BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, November 26, 2024
See today's BioWorld
Home
» Ascletis signs deal for 3-V Biosciences' NASH treatment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ascletis signs deal for 3-V Biosciences' NASH treatment
Feb. 15, 2019
By
David Ho
and
Elise Mak
No Comments
HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640.
BioWorld
